P

Pfizer

Makes cancer drugs, vaccines and other medicines

Regulatory Data Coordinator – Senior Associate

Full-TimePosted on 10/22/2026Deadline 11/5/26
No salary listed
Junior
Bachelor's
Bogotá, Bogota, Colombia+2 moreMore locations: Mexico City, CDMX, Mexico | San José Province, Escazu, Costa Rica
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • At least 2 years of experience in regulatory affairs, data management, data governance, or a related role within the pharmaceutical or healthcare industry.
  • Experience in end-to-end global regulatory change management, including change initiation, impact assessments, submission to Health Authorities, and management of Health Authority decisions, queries, interactions, and commitments.
  • Detailed understanding of regulatory system structures and how they enable regulatory business needs and support compliance.
  • Detailed understanding of regulatory subject matter expert processes and needs across the lifecycle, such as centralized registration procedures, IDMP, CMC, and Artwork/Labeling.
  • Detailed understanding of Global Regulatory Sciences roles and responsibilities related to dossier maintenance and submissions.
  • Strong understanding of data governance principles and best practices.
  • Experience with master data management and data quality improvement.
  • Technical aptitude and ability to quickly learn and use new software, regulations, and quality standards.
  • Attention to detail and commitment to data accuracy and integrity.
Responsibilities
  • Manage RIM events and related records, including event details and registered details, ensuring structures and relationships accurately reflect product market registration, align with master data, and are maintained in line with agency decisions.
  • Interpret Health Authority decisions and interactions, drive appropriate system updates, and collaborate with stakeholders across Global Regulatory Sciences, CMC strategists, PGS, and other teams to understand and meet data requirements.
  • Evaluate and approve data change requests to ensure compliance with data governance policies.
  • Maintain active dossiers across their lifecycle and in alignment with agency decisions.
  • Train and support business users on data quality standards and data and process management best practices.
  • Identify innovative ideas and develop common optimized processes to improve efficiency and effectiveness in supporting products through drug development and commercial lifecycle stages.
  • Ensure escalations, business processes, and solutions meet business needs.
  • Evolve services in line with strategic objectives focused on efficiency and quality.
  • Work with business units, IT, and other stakeholders to understand data requirements and support data-related initiatives.
  • Lead data review and update meetings, and provide guidance and support to system users based on advanced system understanding.
  • Ensure relevant stakeholders are notified when data updates are completed.
  • Generate reports on data quality, data requests, and other relevant metrics.
  • Review event information to understand its purpose and scope, interpret change items, and ensure appropriate event details are updated for impact assessments and Global Product Catalog structures.
  • Use the system wizard to create event details and select appropriate actions and fields.
  • Generate impact assessment reports to identify impacted registrations.
  • Use the system wizard to create activities and related records based on impact assessment reports; verify generated records, confirm their accuracy, identify discrepancies, and ensure data is correctly entered and linked.
  • Coordinate and execute CMC components to facilitate delivery and approval of Pfizer electronic and paper regulatory submissions in accordance with the requirements and standards of each submission and national market.
  • Actively manage status and expected deliverables, identify risks, and partner with regulatory strategists and stakeholders to mitigate risks to quality and timeliness of CMC changes while maintaining accurate metadata in regulatory workflow and document management systems.
Desired Qualifications
  • A B.S./B.Scs. in Pharmacy, Life Sciences, Business, or Information Technology; equivalent relevant professional experience will be considered.
  • Strong communication and collaboration skills.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.